Lenox Wealth Advisors’s Esperion Therapeutics ESPR Stock Holding History

Lenox Wealth Advisors’s Portfolio ESPR Stock Details ESPR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-68	Closed	–	–	833
2021 Q4	$0	Buy	+68	New	+$544	﹤0.01%	974

Other funds holding ESPR

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

PIM

Platinum Investment Management Sydney Australia 2000, Australia $407M AUM 87.11% 1-Year Est. Return

ACM

Altium Capital Management New York $47.5M AUM 115.72% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

Lenox Wealth Advisors's ESPR Position: Q1 2022 in Review

Lenox Wealth Advisors sold out of Esperion Therapeutics (ESPR) in Q1 2022, closing a stake of 68 shares.

Lenox Wealth Advisors first reported a position in ESPR in Q4 2021 and held it in 1 quarter. The position peaked at $0 in Q4 2021. 132 funds tracked by Wall St. Rank hold ESPR as of Q1 2022.

Lenox Wealth Advisors reported no remaining Esperion Therapeutics position as of Q1 2022 after selling out during the quarter.
Lenox Wealth Advisors sold 68 Esperion Therapeutics shares in Q1 2022.
Lenox Wealth Advisors first reported a position in Esperion Therapeutics in Q4 2021 and held it in 1 quarter.
Lenox Wealth Advisors's Esperion Therapeutics position peaked at $0 in Q4 2021.
132 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q1 2022.

Based on Lenox Wealth Advisors's 13F filing for Q1 2022, filed 14 Apr 2022.